
-
Social media helps fuel growing 'sex tourism' in Japan
-
'Pandora's box': alarm bells in Indonesia over rising military role
-
Alaalatoa hails 'hustling hard' Brumbies for rare Super Rugby clean sheet
-
Trio share lead at tight LA Championship
-
Sampdoria fighting relegation disaster as old heroes ride into town
-
Recovering pope expected to delight crowds at Easter Sunday mass
-
Nuggets edge Clippers in NBA playoff overtime thriller, Knicks and Pacers win
-
Force skipper clueless about extra-time rules in pulsating Super Rugby draw
-
Nuggets edge Clippers in NBA playoff overtime thriller, Pacers thump Bucks
-
Unbeaten Miami edge Columbus in front of big crowd in Cleveland
-
Kim takes one-shot lead over Thomas, Novak at RBC Heritage
-
Another round of anti-Trump protests hits US cities
-
'So grateful' - Dodgers star Ohtani and wife welcome first child
-
PSG maintain unbeaten Ligue 1 record, Marseille back up to second
-
US, Iran report progress in nuclear talks, will meet again
-
US Supreme Court intervenes to block Trump deportations
-
Hamas armed wing says fate of US-Israeli captive unknown
-
Pacers thump Bucks to open NBA playoffs
-
Sabalenka reaches Stuttgart semis as Ostapenko extends Swiatek mastery
-
Zelensky says Ukraine will observe Putin's Easter truce but claims violations
-
'Fuming' Watkins fires Villa in bid to prove Emery wrong
-
DR Congo boat fire toll revised down to 33
-
England thrash Scotland to set up France Grand Slam showdown
-
Verstappen's Red Bull 'comes alive' to claim record pole in Jeddah
-
McTominay fires Napoli level with Inter as Conte fuels exit rumours
-
Rajasthan unleash Suryavanshi, 14, as youngest IPL player but lose thriller
-
Man City boost top five bid, Aston Villa thrash in-form Newcastle
-
Villa rout Newcastle to rekindle bid to reach Champions League
-
Dumornay gives Lyon lead over Arsenal in Women's Champions League semis
-
Trans rights supporters rally in London, Edinburgh after landmark ruling
-
'We have to wait': Barca's Flick on Lewandowski injury fear
-
Bordeaux-Begles backups edge Pau to close in on Top 14 summit
-
Trans rights supporters rally outside in London, Edinburgh after landmark ruling
-
PSG beat Le Havre to stay on course for unbeaten Ligue 1 season
-
Man City close in on Champions League with Everton late show
-
14-year-old Vaibhav Suryavanshi becomes youngest IPL player
-
Barca make stunning comeback to beat Celta Vigo in Liga thriller
-
Zverev sets up birthday bash with Shelton in Munich
-
Man City boost top five bid, Southampton snatch late leveller
-
US Supreme Court intervenes to pause Trump deportations
-
Alcaraz and Rune race into Barcelona final
-
US, Iran to hold more nuclear talks after latest round
-
Man City close in on Champions League thanks to Everton late show
-
Bayern close in on Bundesliga title with Heidenheim thumping
-
Tunisia opposition figures get jail terms in mass trial
-
Putin announces 'Easter truce' in Ukraine
-
McLaren duo in ominous show of force in Saudi final practice
-
Afghan PM condemns Pakistan's 'unilateral' deportations
-
Iran says to hold more nuclear talks with US after latest round
-
Comeback queen Liu leads US to World Team Trophy win

US authorizes first condom for use in anal sex
The US Food and Drug Administration (FDA) on Wednesday authorized the first condom for use during anal intercourse, in what was hailed as a victory for sexual health by experts.
Although people already use condoms for anal sex -- as is recommended by health agencies including the Centers for Disease Control and Prevention (CDC) -- regulators across the world had only previously allowed companies to officially market their products as "safe and effective" for vaginal use.
Sexual health advocates considered this an unmet public health need since unprotected anal intercourse carries the greatest risk of HIV transmission via sexual exposure, with one study finding that 69 percent of men who have sex with men would use condoms more frequently if they were FDA-indicated.
Wednesday's authorization of Global Protection Corp's One Male Condom follows a clinical trial involving more than 500 people, carried out by Emory University.
"The FDA's authorization of a condom that is specifically indicated, evaluated and labeled for anal intercourse may improve the likelihood of condom use during anal intercourse," said agency scientist Courtney Lias in a statement.
The condom is also indicated to prevent sexually transmitted infections -- and as a contraceptive -- during vaginal sex.
"We want people to have lots of sex -- but we also want them to be empowered and informed," said Davin Wedel, president of Global Protection Corp, which makes the condom brand that is available in 54 sizes, and incorporates a paper template to help each user find the right size.
The clinical trial involved 252 men who have sex with men and 252 men who have sex with women, aged between 18 and 54.
The FDA had said it would accept a five percent failure rate, which previous trials had failed to accomplish. The limit was easily surpassed in the new study, with the failure rate 0.68 percent for anal and 1.89 percent for vaginal intercourse.
The researchers behind the study, which was published in The Lancet's eClinicalMedicine, said one of the reasons the trial succeeded where others failed in the past was likely due to the provision of lubricant and inclusion of instructions on how to use the product.
Lubricant reduces friction, which in turn causes condom failure from slippage and breakage.
Another reason could be that participants were asked to keep mobile phone-based daily diaries, whereas past trials had asked volunteers to recall failure events up to several months later.
Monica Gandhi, an infectious disease doctor and medical director of an HIV clinic in San Francisco, welcomed the finding.
"The important thing about condoms is they don't just prevent HIV, but they prevent gonorrhea, chlamydia and syphilis," she told AFP, adding it was surprising that such an authorization had taken so long to achieve.
In its statement, the FDA said the green light could pave the way for more makers to apply for similar authorization if they show equivalent results.
K.Thomson--BTB